Stars align for CRISPR Tx, Sirius as pair pens siRNA collab with a focus on thrombotic disease
CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the next-gen thrombotic disease asset SRSD107.
CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the next-gen thrombotic disease asset SRSD107.
